Basic Topics in Toxicology
-
You must log in to register
- Nonmember - $500
- Full Member - $325
- Associate Member - $325
- Emeritus Member - $325
- Government Associate Member - $325
- Government Full Member - $325
- Postdoctoral Researcher/Transitional Member - $175
- Student Member - $175
To further its mission to educate, lead, and serve, the American College of Toxicology is offering an eLearning Seminar focused on the basic topics in toxicology. Basic Topics consists of nine modules that is aimed to provide a strong foundation for an in-depth understanding of the basic concepts and principles of toxicology, pharmacology, drug metabolism, and pharmacokinetics. These modules feature recorded presentations by recognized experts in the field. Modules are available for purchase as a set. Each module is about 90 minutes or less in duration.
Disclaimer:
This seminar reflects the views of the speaker and should not be construed to represent the views or policies of the American College of Toxicology. Examples presented in this seminar may have required unique strategies that do not necessarily apply to other modalities or situations. Regulatory guidelines and best practices are constantly evolving, and the viewer is encouraged to independently confirm their understanding with what was presented in this seminar.
-
Contains 3 Component(s) Recorded On: 08/03/2021
Basic Topics Series
This presentation will focus on principles of general toxicology. The talk will be offered in two segments. In the first segment, an overview of the history of toxicology, how to assess the qualitative and quantitative functions of toxicology, a toxicology primer, the dose-response relationships, the distribution and metabolism of ingested chemicals, and hazard identification will be discussed. The second segment of the session briefly focuses on toxicology in the 21st century (biomonitoring, 3Rs, animal models, and computational toxicology).
$i++ ?>A. Wallace Hayes, PhD, DABT, ATS, FIBiol, FACFE, ERT
Professor
University of South Florida, College of Public Health
Dr. A. Wallace Hayes is a distinguished toxicologist with more than 40 years of experience across academia and industry. He earned his PhD and MS degrees from Auburn University and his AB from Emory University. His early scientific training included service as a National Science Foundation predoctoral fellow at Auburn University, a National Institutes of Health individual postdoctoral fellow at Vanderbilt University School of Medicine, a NATO Senior Scientist at the Central Veterinary Laboratory in Weybridge, England, and a recipient of an NIH Research Career Development Award at the University of Alabama.
Dr. Hayes has held tenured professorships at the University of Alabama, the University of Mississippi Medical Center, and Wake Forest University School of Medicine. His industry leadership roles have included Director of Toxicology and Regulatory Affairs at Rohm and Haas, Vice President at RJR Nabisco, and Corporate Vice President at the Gillette Company. He has also contributed his expertise to committees and expert panels convened by the National Academy of Sciences, the National Institutes of Health, the Environmental Protection Agency, the Food and Drug Administration, and the Department of Defense.
Dr. Hayes has authored more than 460 peer-reviewed publications. He is editor of Hayes’ Principles and Methods of Toxicology, 7th edition, Human and Experimental Toxicology, and Cutaneous and Ocular Toxicology; co-editor of the Target Organ Toxicity series; and co-author of the 4th and 5th editions of Loomis’s Essentials of Toxicology. His professional leadership includes two terms as Secretary-General of the International Union of Toxicology; service as treasurer and board member of the American Board of Toxicology; presidencies of the American College of Toxicology, the Toxicology Education Foundation, and the Academy of Toxicological Sciences; and membership on the council of the Society of Toxicology. He is a diplomate of the American Board of Toxicology, the Academy of Toxicological Sciences, the American Board of Forensic Medicine, and the American Board of Forensic Examiners. He is also a Fellow of the Academy of Toxicological Sciences, the Royal Society of Medicine (UK), the American College of Forensic Examiners, and the American College of Nutrition. He is also a registered toxicologist in the European Union (ERT) and a certified nutrition specialist in food safety. Dr. Hayes’ honors include the Society of Toxicology Merit Award (2006), the Mid-Atlantic Society of Toxicology Ambassador Award (2012), the American College of Toxicology Distinguished Scientist Award (2012), and the Nancy Rollman Service Award (2026), the International Dose-Response Society Outstanding Leadership Award (2013), and the American Academy of Toxicology Mildred S. Christian Career Achievement Award (2021). He was named a Distinguished Fellow of the American College of Toxicology in 2013 and a Fellow of the American Association for the Advancement of Science in 2014.
-
Contains 3 Component(s) Recorded On: 08/05/2021
Basic Topics Series
This eLearning module will focus on the principles of general toxicology. The presentation will provide an overview of the basic tenets of toxicology testing and the general assumptions made during the generation of nonclinical data. It will teach you how to develop a nonclinical safety assessment plan showing you how the safety assessment program is designed regarding general regulations and guidelines and how specific aspects of a chemical/product class can influence the design of the program. The module will also discuss study design considerations for toxicology studies and general regulatory requirements, as well as specific design parameters (route of administration, duration of treatment, selection of species, dose selection, and parameters assessed), briefly explaining large- versus small-molecule development considerations. Moreover, it will highlight the importance of the interpretation of toxicology study results, especially as it concerns to what is an adverse finding and in defining the NOAEL. Finally, the regulatory application of the nonclinical data to clinical dose selection will be covered, ensuring that a comprehensive and robust nonclinical safety assessment package can be submitted in support of new drug applications to regulatory agencies worldwide.
$i++ ?>Lorrene A. Buckley, PhD, DABT, ATS
Vice President
Eli Lilly & Company
Dr. Lorrene Buckley is a board-certified toxicologist with over 30 years of experience in the active practice of toxicology. She earned her degrees in Toxicology, an MS from the University of Arizona, and a PhD from the University of North Carolina at Chapel Hill, in collaboration with the laboratories of the NIEHS and US EPA. She is certified by the American Board of Toxicology (ABT) and is a Fellow of the Academy of Toxicological Sciences (ATS).
Dr. Buckley’s diversity of professional experience as a toxicologist is reflected in her work spanning basic and applied toxicology research and risk assessment in the industrial chemical, agrochemical, and pharmaceutical industries. As a Vice President at Eli Lilly & Company, she was responsible for the design and execution of nonclinical safety assessment programs as well as for nonclinical aspects of global regulatory submissions and interactions for drugs in the development and commercialization phases. Dr. Buckley has authored the pharmacology/toxicology sections of numerous regulatory documents, including briefing documents, INDs/IMPDs, BLAs/NDAs, investigator brochures, annual reports, as well as safety information on product labels/package inserts.
Her contributions to the profession of toxicology include service on the Boards of the ABT and the ATS (past President) and on the Councils of the ACT (past President) and the SOT.
-
Contains 3 Component(s) Recorded On: 08/17/2021
Basic Topics Series
This Basic Topics in Toxicology eLearning module describes the basics of pharmacology and how pharmacology contributes to safety testing. The module begins with an introduction on pharmacology and the purpose of pharmacology studies in drug development. The presentation discusses topics including pharmacodynamics (primary and secondary), drug targets, drug receptor interactions, types of pharmacology studies (primary and secondary), the importance of understanding the physiological system and therapeutic area, and the pharmacology section of drug applications.
$i++ ?>Amy M. Avila, PhD
Pharmacologist/Toxicologist Reviewer, Division of Psychiatry Products, CDER
US FDA
Dr. Avila earned her Bachelor of Science degree in Biochemistry from the University of Delaware. She then received her PhD in pharmacology from Georgetown University, with a focus in neuropharmacology. Her thesis research involved the study of neuronal nicotinic acetylcholine receptors and their functional regulation by nicotine and nerve growth factor. After receiving her PhD, she conducted postdoctoral research at the National Institute of Neurological Disorders and Stroke at the National Institutes of Health. She worked in the Neurogenetics Branch studying the neuromuscular disease Spinal Muscular Atrophy and investigating possible pharmacological therapies using cell-based models and transgenic mouse models. In 2006, Dr. Avila joined the Food and Drug Administration where she is currently serving as a pharmacologist/toxicologist reviewer in the Division of Psychiatry Products in the Center for Drug Development and Research (CDER). She is an active member of the Committee for Advanced Scientific Education in CDER, was a member of the Education Subcommittee of the Pharmacology/Toxicology Coordinating Committee, and has contributed to the development of a training course for new pharmacologist/toxicologist reviewers. Her areas of interest are psychopharmacology, and assessment of seizures in nonclinical drug development.
-
Contains 3 Component(s) Recorded On: 08/05/2021
Basic Topics Series
This lecture explains the basic concepts of absorption, distribution, metabolism, and excretion (ADME) of both small and large molecules. It focuses on toxicokinetic parameters such as Tmax, Cmax, and area under the curve (AUC), bioavailability, and volume of distribution. Various factors that affect ADME parameters, such as physicochemical properties of chemicals, storage depots, drug-metabolizing enzymes, metabolism by intestinal microflora, and elimination kinetics, are discussed. Additionally, monoclonal antibody disposition, distribution, and clearance are also discussed. The application of toxicokinetics in the interpretation of toxicological findings, scaling in dose-response extrapolation, and determining the margin of safety (MOS) is explained using specific examples. Further, characterization of disproportionate metabolites and their safety assessment is discussed. Finally, physiologically based pharmacokinetic modeling capable of accommodating more complex dosing regimens is addressed.
$i++ ?>Debie J. Hoivik, PhD, DABT
Vice President of Early Development
Akebia Therapeutics, Inc.
Dr. Debie Hoivik received her PhD in toxicology from the University of Connecticut and conducted her postdoctoral research at Texas A&M. Since then, she has spent over the last 25 years as a regulatory toxicologist in the pharmaceutical industry (GlaxoSmithKline and Boehringer-Ingelheim), where she was responsible for the nonclinical product development strategy and execution as well as regulatory interactions and submissions for new therapeutic entities. Dr. Hoivik is currently Vice President, Early Development at Akebia Therapeutics, where she is the Program Executive for programs in the Discovery to Clinical Proof of Concept phase of development, as well as having accountability for the toxicology and DMPK disciplines. Dr. Hoivik has authored five invited book chapters, and over 50 manuscripts and abstracts. She has served ACT in a variety of roles (e.g., Councilor, Secretary, Continuing Education Committee, Nominating Committee, Program Committee); she has also been Chair of the SOT Education Committee and served on the SOT Communication Committee; and President of the Northeast Society of Toxicology. Dr. Hoivik has also served on multiple pharmaceutical consortiums and workgroups. She has been a member of the Editorial Review Board for the International Journal of Toxicology and served as a reviewer for Toxicological Sciences. Dr. Hoivik was certified by the American Board of Toxicology in 1999.
-
Contains 3 Component(s) Recorded On: 12/23/2025
Basic Topics Series
With such a diverse set of modalities, from small molecules to biologics, including cell and gene therapies, the decision on how to conduct safety pharmacology studies (or not conduct them at all) could be critical to keeping a drug development program on track. This presentation will focus on considerations for conducting standalone safety pharmacology studies, implementing safety pharmacology endpoints within toxicology studies, or not conducting safety pharmacology studies in support of regulatory submission. When conducting safety pharmacology studies, the critical concern is how to follow the regulations for the new chemical or biological entity and provide the most robust data/results to evaluate safety. This presentation will provide an overview to determine the best approach for your program. Topics covered will be the regulations that support safety pharmacology, the vital organ systems that make up the core battery of studies required prior to first-in-human studies, examples of study designs, and a summary of changes to cardiovascular safety pharmacology based on the revised ICH S7B Q&As for both in vitro and in vivo QT assessments.
$i++ ?>Brian M. Roche, PhD, DSP, DABT
Executive Director of Global Safety Pharmacology
Charles River Laboratories
Dr. Brian Roche is the General Manager at Charles River Laboratories' Kansas site. He has more than 25 years of experience in preclinical drug development, through multiple roles, with a focus on conducting research from early pharmacology through GLP safety pharmacology studies. In his previous role as the Executive Director of Global Safety Pharmacology at Charles River Laboratories, he provided scientific expertise and leadership on behalf of the Global Safety Pharmacology portfolio.
Dr. Roche received his doctorate in cardiovascular physiology from Ohio State University in 2000 under the mentorship of Dr. Robert Hamlin. He continued his education at Ohio State as a postdoctoral research fellow until 2002. He is an active member of the international scientific community and served as President of the Safety Pharmacology Society in 2021.
Dr. Roche is dual boarded as both a Toxicologist (DABT) and Safety Pharmacologist (DSP), has published 25 peer-reviewed scientific papers and a book chapter.
-
Contains 3 Component(s) Recorded On: 08/05/2021
Basic Topics Series
This module will provide an overview of genetic toxicology with a focus on the ICH S2(R1) guideline. Genetic toxicology testing is conducted to assess the ability of drugs to induce gene mutations as well as chromosomal damage (i.e., clastogenicity and aneugenicity). A battery of tests is used to evaluate these endpoints with the goal of predicting human carcinogenic potential. The presentation will cover both in vitro and in vivo genetic toxicology tests with specific discussion of principles and mechanisms, study design, and data interpretation. Decision-making, including discussion of follow-up strategies to mitigate concern with positive results, will be reviewed. In addition, differences in genetic toxicology testing strategies for small-molecule drugs, non-small-molecule drugs, and impurities will be described. Finally, key points will be highlighted through the use of case studies.
$i++ ?>Mark Powley, PhD
Distinguished Research Scientist
Merck & Co., Inc.
Dr. Mark Powley received a PhD in toxicology from Purdue University and completed postdoctoral training at the University of North Carolina – Chapel Hill. From 2004 to 2009 he worked in the general toxicology, biochemical toxicology, and genetic toxicology groups at Merck & Co. In 2009 he moved to the US FDA Center for Drug Evaluation and Research (CDER), Office of New Drugs. In addition to reviewing nonclinical data, Dr. Powley co-chaired CDER pharmacology/toxicology subcommittees focused on genetic toxicology as well as computational toxicology. He was a member of the Genetic Toxicology Association Board of Directors from 2009–2012, serving as chair in 2011–2012. Dr. Powley rejoined Merck & Co. in 2017 and is currently a Distinguished Research Scientist within the Nonclinical Drug Safety organization. His primary role involves supporting mutagenic and non-mutagenic impurity safety assessment efforts.
-
Contains 3 Component(s) Recorded On: 08/05/2021
Basic Topics Series
This Basic Topics eLearning module will focus on the principles of toxicology of key organ systems. The module offers a systematic basic review that will cover the anatomy, physiology, and pathophysiologies of the liver, lung, nervous system, kidney, cardiovascular system, skin, eye, and gastrointestinal system. In addition, classic toxicologic testing strategies for each of these systems will also be discussed as appropriate.
$i++ ?>Mary Beth Genter, PhD, DABT, ATS
Professor
University of Cincinnati
Dr. Mary Beth Genter is a board-certified toxicologist with an interest in all areas of toxicology, with a focus on neurotoxicology and respiratory tract toxicology. Prior to joining the University of Cincinnati Department of Environmental Health (now the Department of Environmental and Public Health Sciences), Dr. Genter earned her PhD from the Integrated Toxicology Program at Duke University, received postdoctoral training at CIIT, and was an Assistant, then Associate Professor in the North Carolina State University Department of Toxicology. Dr. Genter has published over 100 peer-reviewed manuscripts, reviews, and book chapters. Dr. Genter has recently retired from full-time work at the University of Cincinnati as Professor Emerita, while continuing to teach online. She is currently (2009–present) Editor-in-Chief of International Journal of Toxicology, the official journal of the American College of Toxicology. Other service to the field of toxicology includes past participation as a member of the North Carolina Secretary’s Scientific Advisory Board on Toxic Air Pollutants; service as an advisor to the US EPA for the IRIS reevaluation of naphthalene; service as a member of the ABT Board of Directors (2004–2008); service on the National Toxicology Program Board of Scientific Counselors (2013–2017); participation on the IARC Monograph Volume 140 panel (2025); and as a member of the National Academies Committee on Review of Methods in the Report on Carcinogens Handbook (2026).
-
Contains 3 Component(s) Recorded On: 08/05/2021
Basic Topics Series
This module aims to provide an overview of Reproductive, Developmentalม and Juvenile Toxicology with a focus on the nonclinical testing of drugs, medical devices, and vaccines (intentional exposures) and chemicals, food additives, etc. (unintentional exposures), for effects on male and female fertility and early embryonic development, embryofetal development (EFD), pre- and postnatal (PPND) development and direct exposure postnatally.
The regulatory guidance for testing of reproductive and developmental drugs and chemical toxicants, including the newly approved ICH S5(R3) (18 Feb 2020) and OECD 421/422/414/443, will be discussed. Included are overviews of study designs, reasons for species selection, and appropriate age of animals for testing. The presentation will cover the various stages of male and female fertility/reproduction, fetal development and growth, and development of future generations; data interpretations on the toxicity endpoints (paternal/maternal/ developmental/juvenile) and outcomes, including the establishment of a no-observed-adverse-effect-level (NOAEL) and hazard assessments. The reproductive and developmental testing of biologics, biopharmaceuticals, and vaccines, including species selection, enhanced/combined study designs, appropriate organ and other toxicity assessments, and outcomes, are also discussed.
The last part of this module will focus on the principles of Juvenile Toxicology and address whether a juvenile animal study should be conducted, the timing of juvenile studies when needed, and how it should be conducted. An overview of juvenile toxicology guidelines, including the ICH S11 guidance for nonclinical juvenile animal testing to support pediatric medicine development will be presented. This will include a weight-of-evidence approach to decide when a juvenile animal study is warranted. Topics addressed will include selection of juvenile toxicology species, age of the animals, dose range finding, and ADME considerations in juvenile animals. Lastly, interpretation considerations unique to juvenile animal studies and application of results to human risk assessment will be discussed with a focus on pharmaceuticals.
$i++ ?>Alan M. Hoberman, PhD, DABT, ATS
President
Argus International, Inc.
Dr. Alan Hoberman has been employed by Charles River Laboratories, Horsham, Pennsylvania (formerly Argus Research Laboratories, Inc.) since 1981, serving as Study Director, Director of Reproductive Toxicology, Executive Director, Global Developmental, Reproductive and Juvenile Toxicology and Scientific Advisor. He is also the President of Argus International Inc. a consulting company. Prior to joining Argus Research, Dr. Hoberman was the Head of Reproductive Toxicology at Hazleton Laboratories in Vienna, Virginia. He received his BS in Biology from Drexel University and was a graduate student in Anatomy at the University of Virginia before moving to Arkansas and completing a MS in Interdisciplinary Toxicology from the University of Arkansas and a PhD in Toxicology from Pacific Western University.
He is a Diplomat of the American Board of Toxicology since 1988 and a Fellow of the Academy of Toxicological Sciences since 2006, with over 95 publications and book chapters. He is the co-editor of “Pediatric Non-Clinical Drug Testing, Principles, Requirements, and Practices” published in January 2012.
Dr. Hoberman has been a member of Birth Defects Research and Prevention since 1978 and is a Past President. He is also a member of the European Teratology Society since 1982 and past councilor. He has been a member of the American College of Toxicology since 1979 and is a Past President. He is a Past President of the Reproductive and Developmental Toxicity Specialty Section of the Society of Toxicology, the Middle Atlantic Reproductive and Teratology Association, and the Arkansas Biotechnology Organization. He currently represents the 3Rs Collaborative on the Scientific Liaison Collation.
-
Contains 3 Component(s) Recorded On: 12/25/2025
Basic Topics Series
This presentation provides a stepwise overview of evaluating potential carcinogenicity in rodents, with a focus on pharmaceuticals. Following a brief history of chemical carcinogenicity, the presentation outlines possible study objectives, recommendations for carcinogenicity studies set by regulatory agencies, and key factors in designing a strategy to evaluate and predict carcinogenicity. The presentation covers specific topics related to planning a carcinogenicity study, study design, internal and regulatory review of carcinogenicity study protocols, and study oversight and interpretation. The presentation also discusses weight-of-the-evidence approaches for both small molecules and biologics. The presentation concludes by addressing the interpretation of “positive” results for assessing human safety, the regulatory implications of a “positive” study, and provides examples of how positive carcinogenicity study findings are addressed in product labeling.
$i++ ?>Timothy McGovern, PhD
Principal Consultant
White Oak Regulatory Tox, LLC
Dr. Timothy McGovern is a co-founder and Principal Consultant of White Oak Regulatory Tox, LLC, where he provides advice to pharmaceutical companies related to all aspects of nonclinical programs intended to support pharmaceutical drug development from first in human clinical trials to marketing applications.
Dr. McGovern recently completed a 22-year career at the US Food and Drug Administration (FDA) where he spent the past 11 years as an Associate Director for Pharmacology and Toxicology in the Office of New Drugs (OND) of the Center for Drug Evaluation and Research (CDER). He served as a member of the Pharmacology/Toxicology Senior Leadership Team within OND and was responsible for the development of policy and guidance related to nonclinical and regulatory issues including FDA and International Council for Harmonization (ICH) guidance initiatives. He was also a standing member of CDER’s Executive Carcinogenicity Assessment Committee as well as CDER’s Genetic Toxicology and Pharmacology/Toxicology Education Subcommittees.
Dr. McGovern was a member of multiple ICH Expert Working Groups including S1B (Testing for Carcinogenicity of Pharmaceuticals), M7 (DNA reactive impurities), Q3C (Residual Solvents), and Q3D (Elemental Impurities), serving as Topic Lead and Rapporteur. Dr. McGovern was also a member of CDER’s Task Force on Nitrosamines in Drug Products providing nonclinical expertise in developing policies, addressing clinical safety issues, and interacting with other Drug Regulatory Agencies and Industry stakeholders. He participated in drafting FDA’s Guidances “Control of Nitrosamine Impurities in Human Drugs” and “Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs)” and served as Chair of the CDER Pharm/Tox Nitrosamines Working Group.
Dr. McGovern earned a doctorate degree in inhalation toxicology from New York University and first joined OND’s Division of Pulmonary and Allergy Products (DPAP) as a primary reviewer. He later supervised review teams in DPAP as well as the Division of Anesthetic and Critical Care Products.
Registration Fees:
Seminar registration is restricted to single person use only. Please note that all eLearning sales are final. No cancellations or refunds will be allotted after payment is processed.
| Registration Type | Set/Module 1–9 |
| ACT Member | $325 |
| ACT Student/Transitional/Postdoctoral Researcher Member | $175 |
| Nonmember | $500 |
*Fees are assessed according to membership status at the time of purchase. There are no exceptions and no refunds after payment has been processed.
The Basic Topics in Toxicology eLearning Seminar content will only be available until December 31, 2027.